Cincinnati, OH -- (SBWIRE) -- 07/07/2017 -- M Pharmaceutical Inc., (the "Company" or "M Pharma"), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the US Orphan Drug Act. This new drug and its orphan status should also qualify for a Rare Pediatric Disease designation and a Priority Review Voucher (PRV). PRV's are incentives designed by the FDA to spur the development on new treatments for diseases that would otherwise not attract development interest from companies due to the cost of development and lack of market opportunities (very small patient populations). M Pharma has structured the in-license agreements by forming a private joint venture LLC with the inventor and group of private investors associated with inventor, as minority stakeholders.

"We have an opportunity with this new technology to fill an unmet pediatric need," said Gary Thompson, President and CEO of M Pharma. "Current treatments on the market can run in the hundreds of thousands / years for treatments and none are FDA approved for infants younger than two years of age," said Mr. Thompson.

"Our goal is to not only provide assistance to families fighting these Rare Pediatric Diseases but to also add a valuable Priority Review Voucher asset to M Pharma that offers the potential of a third-party transfer for hundreds of millions of dollars, which would be used to fund additional drug development," added Mr. Thompson.

About Orphan Drug Development, Rare Pediatric Diseases and Priority Review Vouchers
Orphan Drug Act: Since the 1984 passage of the Orphan Drug Act, the US has begun to recognize that incentives can help spur development of new drugs for historically under-served conditions. Under the Orphan Drug Act, companies are eligible for several extra years of marketing exclusivity, during which time FDA is not permitted to approve a generic, as additional benefit for getting a "rare" disease drug approved. This gives companies an added incentive to produce drugs intended for rare diseases; it allows the company extra time to recoup its development costs and likely turn a profit as well.

Priority Review: Most drugs are reviewed by FDA under "standard" review times; meaning FDA has 10 months to review each product before it is supposed to render a decision. However, the review clock stops each time the FDA requests additional information from a sponsor, adding several months to the review process. However, for certain drugs, FDA accelerates its regulatory review in the hopes of getting products to market more quickly. For companies and patients alike, FDA's priority review process can be extremely beneficial; for companies, it means they can market their product more quickly and begin recouping their often-considerable development costs.

Priority Review Voucher: FDA's priority review vouchers are incentives meant to spur the development of new treatments for diseases that would otherwise not attract development interest from company's due to the cost of development and the lack of market opportunities. To do this, companies are given a special voucher which allows them to have any one of their drugs reviewed under FDA's priority review system.

Rare Pediatric Disease Voucher: The rare pediatric voucher was created in 2012 under the Food and Drug Administration Safety and Innovation Act (FDASIA), and specifically targets the need for additional therapies for rare pediatric subsets of other diseases. Section 908 of FDASIA defines a "rare pediatric disease" as one which "primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children and adolescents," and is a rare disease according to federal statute (200,000 persons in the US or fewer).

Priority Review Voucher Sale & Transfer: PRV's, as mentioned above, can be sold to other companies for expedited/priority review of any drug under development. BioMarin's voucher, the first ever to be sold, was purchased for $67 million. Several months later, Gilead Sciences purchased Knight Therapeutics' voucher for $125 million. In May 2015, Sanofi purchased yet another voucher for a record-setting $245 million, and in August 2015, AbbVie shattered that record by paying $350 million for a voucher originally awarded to United Therapeutics. However, since then the selling price for PRVs has continued to slide, with Gilead paying $200 million for a voucher in 2016, and $125 million for one in February 2017.

About M Pharmaceutical
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J's LLC, the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive sometime in the third quarter of 2017.

M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company's biomedical & drug technologies, the value of priority review vouchers and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices:
C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 01/25/2017 -- M Pharmaceutical Inc. (the "Company" or "M Pharma"), announced today as part of its planned acquisition of 40 J's, that it will immediately seek marketing and distribution partnerships for the patented and proprietary topical products for the relief of menopausal symptoms that will be part of the assets being acquired. There are approximately 65 million women in North America currently nearing or experiencing menopause.

"Menopause is a natural occurrence in women brought about by the decline of the secretion of hormones by a women's body. In many instances, hormone replacement therapy (HRT) is a standard medical treatment for these symptoms, but the strong synthetic hormones prescribed for HRT often lead to many undesirable side effects," said Gary Thompson, President & CEO of M Pharmaceutical USA.

"Our product's innovative topical formulation of menthol and L-arginine, paired with other key, naturally occurring phytoestrogens, has been shown to improve the symptoms of menopause without the unwanted side effects sometimes associated with standard HRT treatments. Our goal is to have distribution contracts in place and product shipping by mid-summer," said Mr. Thompson.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as To Conceive that represents its first offering in the women's health field.

Notice regarding Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company's biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices:
C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 01/19/2017 -- M Pharmaceutical Inc.,(the "Company" or "M Pharma"), announced today as part of its planned acquisition of 40 J's, that it will immediately seek marketing and distribution partnerships for its topical products for the relief of Diabetic Neuropathy symptoms.

"Diabetic Neuropathy, or diabetic nerve pain, is a result of permanent damage to the nerves of the hand and feet caused by elevated blood sugar levels. This pain is different from pain you may have experienced from arthritis, a headache or even a sports injury," said Gary Thompson, President and CEO of M Pharmaceutical USA. "Diabetic pain often times is so intense that it can affect the simplest of day to day activities for over 400 million people worldwide battling this disease. Our product's innovative topical formulations of menthol and L-arginine paired with other key ingredients has been shown to ease this hand and leg pain. Our goal is to have distribution contracts in place and product shipping by mid-summer," said Mr. Thompson.

About M Pharmaceutical Inc
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field.

Notice regarding Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company's biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices:
C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 01/12/2017 -- M Pharmaceutical Inc., (the "Company" or "M Pharma"), announced that, as part of its planned acquisition of 40 J's, it will continue to advance the development of a patented (additional patents pending) topical drug product for the treatment of female sexual dysfunction (FSD).

"Unlike the other two drugs approved by the US FDA to treat FSD, our topical drug product would focus on women with orgasm and arousal difficulties. Valeant's Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA imposed prescription and marketing restrictions. Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions. Our proposed treatment is topical, local and non-systemic, with daily and on demand use, while being non-hormonal and not a central nervous system drug. Based on these core attributes, the safety profiles of the API and excipients in the drug product, the dosage and delivery form, we anticipate the product to be extremely well tolerated and highly effective for a large number of women suffering from FSD and has a great likelihood of approval by the FDA," said Mr. Thompson, CEO of M Pharmaceutical USA.

About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as To Conceive that represents its first offering in the women's health field.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company's biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. able outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 01/05/2017 -- M Pharmaceutical Inc., (the "Company" or "M Pharma"), is announcing today that the company has executed on a Letter of Intent to acquire the assets of Cincinnati based private research and development partnership 40J's LLC (and related companies & technologies). In return for approximately 80 million shares and $1.5 million in cash to be issued or paid over the next two years, together with certain milestone payments, the Company will acquire 100% of the worldwide rights to these products and technologies. The transaction is subject to due diligence, exchange approval and other normal closing requirements for transactions of this nature.

Over the past 17 years, 40J's, its co-companies and principals have developed numerous patented and patent pending technologies for a wide range of medical concerns with a focus on female and male reproductive health, diabetes, weight loss and other quality of life concerns.

"This acquisition is a very exciting advancement for M Pharma", said Gary Thompson CEO of M Pharmaceutical USA. "Like M Pharma, 40J's is a company committed to developing and commercializing innovative treatments and technologies to offer patients and consumers effective solutions to quality of life concerns; these are based on the overreaching principles of reduced invasiveness and improved effectiveness. The companies' extensive list of patented and patent pending technologies not only builds upon M Pharma's current pipeline of product innovation, but also brings current distribution partners & ongoing business development, harmonizes operations and R&D initiatives, and adds existing inventory & revenue to our bottom line," said Mr. Thompson.

About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company's biomedical & drug technologies, and the acquisition of the rights to a new product. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 10/11/2016 -- M Pharmaceutical Inc., (the "Company" or "M Pharma"), is pleased to announce that it has engaged Camargo Pharmaceutical Services, in order to help C-103 is a novel formulation of Orlistat, patented until 2030 in the United States. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter). Orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007. C-103 is intended to maintain the efficacy of Orlistat while minimizing its socially unacceptable side effects.

Known for their experience and expertise in 505(b)(2) drug development, Camargo Pharmaceutical Services provides guidance to navigate the complex regulatory landscape via the most time- and cost-effective path forward. Camargo ensures FDA buy-in, and aligns complete development plans with business strategies. Camargo routinely leads up to 6 meetings with the FDA per month, has guided more than 200 FDA approvals, and works with product developers from more than 25 countries.

"At Camargo, we focus on providing guidance through all aspects of drug development, ensuring our client-partners' programs advance through the regulatory process, gain approval, and commercial success," said Dr. Ruth Stevens, Chief Scientific Officer and Executive Vice President of Camargo Pharmaceutical Services. "We look forward to working with M Pharma on their C-103 reformulation of Orlistat."

"At this exciting and critical stage in the development of C-103, our leadership team and Advisory Board believe it is prudent and necessary to benefit from Camargo's guidance and expertise. This alliance will strengthen our effort and expedite the process to bring C-103 to market, benefiting millions of potential people looking for solutions to reach and maintain a healthy weight," noted Mr. Brian Keane, President and CEO of the Company.

About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company's biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Vancouver, BC -- (SBWIRE) -- 10/06/2016 -- M Pharmaceutical Inc., (the "Company" or "M Pharma"), is announcing that the Company has entered into a letter of intent to acquire from ToConceive LLC., a private pharmaceutical company, the rights to an FDA approved women's health product, used as a natural conception lubricant as an infertility treatment. This acquisition is subject to further due diligence and stock exchange approval, and would see the Company issue 20 million shares and agree to pay a 5% royalty on sales.

- An estimated 7.1 million couples in the United States are struggling with infertility
- ToConceive is positioned to capture a percentage of the $3 billion spent annually on assisted reproduction in the U.S.
- ToConceive is FDA approved, gynecologist discovered and clinically proven
- Average cost of IVF Treatment in the U.S. is $13,000
- Cost of three months of ToConceive is $120

As M Pharma is well underway with its development of its recently acquired patented Chelatexx technology, the Company is taking steps to broaden its portfolio of drug treatments and biomedical technologies.

ToConceive is an easy to use natural conception lubricant this is applied on the outside of a woman's genitalia and stimulates a natural self-produced arousal vaginal lubrication in the woman. This natural conception lubrication balances the pH of the vagina to support sperm survival. It also transforms the sperm to give the sperm the ability, or capacity, to fertilize the ovum for conception, a process called sperm capacitation.

"In 2010 the Nobel Prize in Medicine for In Vitro Fertilization emphasized the importance of Sperm Capacitation -the process when a women's natural conception lubrication, transudate, dissolves the immobilizing cholesterol from the sperm and creates an enzyme to allow the sperm to fertilize the ovum - for successful conception. This essential capacitation step is inadequate or missing in many couples due to the women's limited production of transudate," noted Mr. Gary Thompson, CEO of M Pharma USA.

"ToConceive has a 510K FDA clearance, is protected by four USPTO patents, and is clinically proven to increase a women's production of transudate. This increase in transudate results in significantly higher success rates for couples trying to conceive without the added expense, or stress, associated with assisted reproduction treatments," added Mr. Thompson.

"This acquisition is our entry into the women's health market to complement our existing obesity portfolio. We are confident this product presents a potential breakthrough in the women's health space due to its ease of use as a personal lubricant and its effectiveness, both clinically and from a cost standpoint," added Brian Keane, CEO of the Company.

About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company's biomedical & drug technologies, and the acquisition of the rights to a new product. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on http://www.sedar.com and the Company's filings to the CSE at http://www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm